MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ando, A.
Right arrow Articles by Campochiaro, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ando, A.
Right arrow Articles by Campochiaro, P. A.

Vol. 62, Issue 3, 539-544, September 2002

Blockade of Nitric-Oxide Synthase Reduces Choroidal Neovascularization

Akira Ando,1 Amy Yang, Hiroyuki Nambu, and Peter A. Campochiaro

Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Nitric oxide (NO) promotes retinal and choroidal neovascularization, although different isoforms of nitric-oxide synthetase (NOS) are critical in each. Deficiency of endothelial NOS (eNOS) suppresses retinal but not choroidal neovascularization, whereas deficiency of neuronal NOS (nNOS) or inducible NOS (iNOS) suppresses choroidal, but not retinal neovascularization. In this study, we investigated the effect of NG-monomethyl-L-arginine (L-NMMA), a nonspecific NOS inhibitor, in three models of ocular neovascularization. Oral administration of L-NMMA caused significant inhibition of choroidal neovascularization in mice with laser-induced rupture of Bruch's membrane and significantly inhibited subretinal neovascularization in transgenic mice with expression of vascular endothelial growth factor (VEGF) in photoreceptors (rho/VEGF mice) but did not inhibit retinal neovascularization in mice with ischemic retinopathy. By extensive mating among mice deficient in NOS isoforms, triple homozygous mutant mice deficient in all three NOS isoforms were produced. These mice had marked suppression of choroidal neovascularization at sites of rupture of Bruch's membrane and near-complete suppression of subretinal neovascularization in rho/VEGF mice but showed no difference in ischemia-induced retinal neovascularization compared with wild-type mice. These data indicate that NO is an important stimulator of choroidal neovascularization and that reduction of NO by pharmacologic or genetic means is a good treatment strategy. However, the situation is more complex for ischemia-induced retinal neovascularization for which NO produced in endothelial cells by eNOS is stimulatory, but NO produced in other retinal cells by iNOS and/or nNOS is inhibitory. Selective inhibitors of eNOS may be needed for treatment of retinal neovascularization.


1 Present address: Kansai Medical University, Moriguchi, Osaka, Japan


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
IOVSHome page
H. She, T. Nakazawa, A. Matsubara, T. Hisatomi, T. A. Young, N. Michaud, E. Connolly, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller
Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2268 - 2277.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
H. Nambu, R. Nambu, M. Melia, and P. A. Campochiaro
Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3650 - 3655.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
W. Kozak and A. Kozak
Genetic Models in Applied Physiology: Selected Contribution: Differential role of nitric oxide synthase isoforms in fever of different etiologies: studies using Nos gene-deficient mice
J Appl Physiol, June 1, 2003; 94(6): 2534 - 2544.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics